Surrozen (SRZN) Price & Analysis

Compare

40 Followers

SRZN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.90 - $18.17

Previous CloseN/A

Volume12.23K

Average Volume (3M)19.04K

Market Cap

$117.07M

Enterprise Value-$6.52M

Total Cash (Recent Filing)$90.39M

Total Debt (Recent Filing)$7.51M

Price to Earnings (P/E)―

Beta-0.24

Next Earnings

Nov 17, 2025

EPS Estimate

-1.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)2.55

Shares Outstanding8,570,355

10 Day Avg. Volume32,778

30 Day Avg. Volume19,044

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.06

Enterprise Value/Revenue-0.52

Enterprise Value/Gross Profit-0.49

Enterprise Value/Ebitda0.26

Forecast

1Y Price Target

$37.00

Price Target Upside168.70% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Industry ValidationStrategic validation of the Wnt pathway has been demonstrated by acquisitions from major companies like Merck and Roche, supporting the Wnt mechanism.

Research ProgressThe company recently presented preclinical data for assets SZN-8141 and SZN-8143 at major annual meetings, indicating progress in their research focus.

Strategic PartnershipsThe collaboration and licensing agreement with Boehringer Ingelheim for bi-specific antibody SZN-413 provides upside beyond the internal Wnt pipeline for vascular pathology.

Bears Say

Development DelaysThe internal clinical development is on the longer-term horizon with candidate SZN-8141 IND submission anticipated in 2026, suggesting a delay in market availability.

Therapeutic ChallengesSurrozen previously discontinued former lead candidate SZN-043 based on Phase 1b development for severe alcohol-associated hepatitis, indicating challenges in certain therapeutic areas.

Surrozen News

Surrozen Signs $50M Sales Agreement with TD Securities

The latest update is out from Surrozen ( ($SRZN) ). On August 29, 2025, Surrozen, Inc. entered into...

1M ago

SRZN

Surrozen’s Innovative Wnt Pathway Approach Garners Buy Rating Amid Promising Preclinical Data

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Surrozen, with a...

2M ago

SRZN

Surrozen’s Q2 2025: Progress in Eye Disease Therapies

Surrozen, Inc. ( ($SRZN) ) has released its Q2 earnings. Here is a breakdown of the information Surrozen,...

2M ago

SRZN

Surrozen files $150M mixed securities shelf

16:33 EDT Surrozen (SRZN) files $150M mixed securities shelf Published first on TheFly – the ultimate source for...

5M ago

SRZN

Surrozen Holds Successful 2025 Annual Stockholders Meeting

Surrozen ( ($SRZN) ) has issued an update. On May 14, 2025, Surrozen, Inc. held its 2025 Annual...

5M ago

SRZN

Surrozen granted patent from USPTO directed to antibody-based molecules

Surrozen (SRZN) announced the issuance of U.S. Patent No. 12,297,278. Surrozen has six issued U.S. patents, 10 patents...

5M ago

SRZN

Surrozen’s Strategic Focus on Wnt Pathway and Promising Pipeline Earns Buy Rating

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Surrozen (SRZN – Research Report) today and set...

5M ago

SRZN

Surrozen, Inc. Reports Q1 2025 Financial Results

Surrozen, Inc. ( ($SRZN) ) has released its Q1 earnings. Here is a breakdown of the information Surrozen,...

5M ago

SRZN

Surrozen files to sell 5.21M shares of common stock for holders

The company is not selling any of its common stock pursuant to this prospectus, and will not receive...

5M ago

SRZN

Surrozen’s Strategic Shift to Ophthalmology and Wnt Pathway Innovations Justify Buy Rating

Analyst Matthew Caufield of H.C. Wainwright reiterated a Buy rating on Surrozen (SRZN – Research Report), retaining the...

6M ago

SRZN

Surrozen Focuses on Ophthalmology Amid Financial Challenges

Surrozen, Inc. ( ($SRZN) ) has released its Q4 earnings. Here is a breakdown of the information Surrozen,...

6M ago

SRZN

Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year

Cash and cash equivalents were $34.6M as of December 31, compared to $31.0M as of September 30 and...

6M ago

SRZN

Surrozen Secures $76.4M in Private Placement Deal

The latest update is out from Surrozen ( ($SRZN) ). On March 24, 2025, Surrozen, Inc. entered into...

6M ago

SRZN

Surrozen to focus Wnt expertise, technologies on ophthalmology programs

Surrozen (SRZN) announced that the company will focus its Wnt biology expertise and Wnt signal modulation antibody technologies...

6M ago

SRZN

SRZN FAQ

What was Surrozen’s price range in the past 12 months?

Surrozen lowest stock price was $5.90 and its highest was $18.17 in the past 12 months.

What is Surrozen’s market cap?

Surrozen’s market cap is $117.07M.

When is Surrozen’s upcoming earnings report date?

Surrozen’s upcoming earnings report date is Nov 17, 2025 which is in 44 days.

How were Surrozen’s earnings last quarter?

Surrozen released its earnings results on Aug 08, 2025. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of -$1.11 by $3.66.

Is Surrozen overvalued?

According to Wall Street analysts Surrozen’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Surrozen pay dividends?

Surrozen does not currently pay dividends.

What is Surrozen’s EPS estimate?

Surrozen’s EPS estimate is -1.14.

How many shares outstanding does Surrozen have?

Surrozen has 8,570,355 shares outstanding.

What happened to Surrozen’s price movement after its last earnings report?

Surrozen reported an EPS of $2.55 in its last earnings report, beating expectations of -$1.11. Following the earnings report the stock price went up 4.393%.

Which hedge fund is a major shareholder of Surrozen?

Currently, no hedge funds are holding shares in SRZN

Surrozen Stock Smart Score

Underperform

Fundamentals

Return on Equity

-130.27%

Trailing 12-Months

Asset Growth

127.85%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Surrozen

Surrozen, Inc. (SRZN) is a biotechnology company focused on harnessing the regenerative properties of the Wnt signaling pathway to develop novel therapeutics. The company is engaged in the research and development of treatments that aim to address unmet medical needs across various therapeutic areas. Surrozen's core products are designed to stimulate tissue regeneration and repair, potentially offering new solutions for diseases where current treatment options are limited.

Surrozen (SRZN) Earnings & Revenues

Historic Earnings Reports

SRZN Stock 12 Month Forecast

Average Price Target

$37.00

▲(168.70% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","62":"$62","115":"$115","35.5":"$35.5","88.5":"$88.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$37.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$32.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,35.5,62,88.5,115],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2022","6":"Apr<br/>2024","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.32,14.603076923076923,16.886153846153846,19.169230769230772,21.45230769230769,23.735384615384618,26.01846153846154,28.301538461538463,30.584615384615386,32.86769230769231,35.15076923076923,37.433846153846154,39.71692307692308,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.32,14.218461538461538,16.116923076923076,18.015384615384615,19.913846153846155,21.81230769230769,23.71076923076923,25.60923076923077,27.50769230769231,29.406153846153845,31.304615384615385,33.20307692307692,35.10153846153846,{"y":37,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.32,13.833846153846155,15.347692307692308,16.861538461538462,18.375384615384615,19.88923076923077,21.403076923076924,22.916923076923077,24.43076923076923,25.944615384615386,27.45846153846154,28.97230769230769,30.486153846153847,{"y":32,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":114.38,"date":1630454400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.1,"date":1633046400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.15,"date":1651363200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.3,"date":1664582400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.85,"date":1667260800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":16.95,"date":1677628800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":10.1,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.23,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14.35,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.12,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.48,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >